ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
In: Blood, Jg. 140 (2022-11-15), S. 3341-3343
Online
unknown
Zugriff:
Titel: |
ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
|
---|---|
Autor/in / Beteiligte Person: | Andrew H Wei ; Harry J Iland ; Reynolds, John ; Loo, Sun ; Chong Chyn Chua ; Westerman, David ; Ing S Tiong ; Ivey, Adam ; Blombery, Piers ; Natasha S Anstee ; Rachel M Koldej ; Curtis, David J. ; Kipp, David ; Ritchie, David ; David M Ross ; Souza, Amanda ; Collins, Jenny ; Bajel, Ashish ; Grove, Carolyn ; Marlton, Paula ; Andrew W Roberts ; Pemmaraju, Naveen ; Patel, Keyur P. ; Loghavi, Sanam ; Konopleva, Marina ; Daver, Naval ; DiNardo, Courtney D. |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), S. 3341-3343 |
Veröffentlichung: | American Society of Hematology, 2022 |
Medientyp: | unknown |
ISSN: | 1528-0020 (print) ; 0006-4971 (print) |
DOI: | 10.1182/blood-2022-167837 |
Schlagwort: |
|
Sonstiges: |
|